Salem Media Reignites Partnership with KeepTheFaith, America's #1 Syndicated Faith-Based Entertainment Radio Show, Across 28 Owned and Operated Stations and 10 Translators
This move comes in direct response to strong listener demand and continued advertiser support, reaffirming KeepTheFaith's status as a cornerstone in inspirational broadcasting. The show currently airs on more than 230 stations across the U.S. and Canada, including 19 of the top 20 radio markets.
Hosted by the dynamic trio of Keith Stevens, Donna Cruz, and "Penny," along with a cast of rotating contributors, KeepTheFaith uniquely blends uplifting music with powerful, real-life stories. Its signature storytelling format is supported by a digital archive of more than 50,000 premium content pieces—featuring New York Times best-selling authors, platinum-selling recording artists, renowned motivational speakers, heroic newsmakers, and ordinary people overcoming extraordinary adversity through faith.
David Santrella, CEO of Salem Media Group, shared, 'We're excited to welcome KeepTheFaith back to our airwaves. For more than a decade, they've been a vital programming partner with content that's unmatched in our industry. Listener enthusiasm and advertiser confidence played a major role in our decision to feature the show on our teach/talk stations. With over 4,000,000 monthly listeners, we're excited to continue to partner with Keep the Faith.'
David Sams, CEO of KeepTheFaith Media Networks, added, 'By the grace of God, we're incredibly grateful to continue our long-standing partnership with Salem. This new chapter empowers us to serve listeners in fresh, impactful ways—on stations that are brand new to this format. We're honored to bring contagious encouragement to millions and offer advertisers an energizing new way to connect with this loyal audience.'
In addition to its expansive radio presence, KeepTheFaith Radio now streams 24/7 on iHeartRadio, Audacy, TuneIn, Alexa, and Google Home, and via the company's robust digital platform at KeepTheFaith.com.
All broadcast and streaming platforms are nationally represented by Salem Media Reps for advertising sales.
About KeepTheFaith Media Networks, a BigOyo, LLC company:
KeepTheFaith is America's #1 syndicated faith-based radio program, airing on more than 230 stations across North America. Known as "the home of contagious encouragement," KeepTheFaith blends uplifting music, real-life stories, and practical wisdom to support and inspire millions each week.
KeepTheFaith Media Networks delivers programming across multiple formats, including Contemporary Christian Music (CCM), Country, Adult Contemporary (AC), and now Teach/Talk, making it one of the most versatile and widely distributed inspirational radio brands in North America.
KeepTheFaith programming includes:
KeepTheFaith Sunday Morning with Keith Stevens and Donna Cruz, now in its 14th season
KeepTheFaith with Penny, airing weeknights, Monday through Friday
KeepTheFaith.com, delivering premium content on demand, 24/7 through the network's digital streaming platform
HDL: HyperDrive Local, daily digital syndicated content provider to stations, giving them stories and phone calls to fit into any daypart
All shows are available to stations via FTP, with or without music, providing maximum flexibility for various station formats.
About Salem Media Group, Inc.:
Salem Media Group is America's leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners, readers and viewers numbering in the millions nationally. With its unique content focus, Salem provides compelling audio and video programming, text content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at www.salemmedia.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 minutes ago
- Business Wire
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. 'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.' About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.
Business Wire
8 minutes ago
- Business Wire
The Toro Company to Announce Fiscal 2025 Third Quarter Results
BLOOMINGTON, Minn.--(BUSINESS WIRE)--The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, today announced that it will release its fiscal 2025 third quarter results on Thursday, September 4, at approximately 7:30 a.m. CT. The full text of The Toro Company's earnings release will be available at that time at The company will also hold an earnings conference call at 10 a.m. CT that day. A live, listen-only webcast of the earnings conference call will be available at Visitors are encouraged to go to the website in advance of the call to register, and download and install any necessary audio software. A replay will be available on the website shortly following the call. About The Toro Company The Toro Company (NYSE: TTC) is a leading global provider of solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. With net sales of $4.6 billion in fiscal 2024, The Toro Company's global presence extends to more than 125 countries through a family of brands that includes Toro, Ditch Witch, Exmark, Spartan, BOSS, Ventrac, American Augers, Subsite, HammerHead, Radius, Perrot, Hayter, Unique Lighting Systems, Irritrol, and Lawn-Boy. Through constant innovation and caring relationships built on trust and integrity, The Toro Company and its family of brands have built a legacy of excellence by helping customers work on golf courses, sports fields, construction sites, public green spaces, commercial and residential properties and agricultural operations. For more information, visit
Business Wire
8 minutes ago
- Business Wire
Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Guess?, Inc. (NYSE: GES) will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, on Wednesday, August 27, 2025. The financial results will be accessible at via the 'Investor Relations' link. In light of the pending take-private transaction announced separately today, Guess? will not host a conference call in connection with its quarterly results. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. At May 3, 2025, the Company directly operated 1,074 retail stores in Europe, the Americas and Asia. The Company's partners and distributors operated 527 additional retail stores worldwide. At May 3, 2025, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit
